Also trades as: 0T6G.L (LSE) · $vol 0M
QTTB NASDAQ
Q32 Bio Inc.
1W: +1.0%
1M: -5.6%
3M: -40.5%
YTD: +153.2%
1Y: +193.3%
3Y: -53.0%
5Y: -92.1%
$8.71
+0.26 (+3.08%)
Weekly Expected Move ±11.2%
$7
$8
$9
$10
$11
Credit Risk of going bust: higher than 79% of companies Debt: 2.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.04 (down 99.5%), Q32 Bio Inc. would be worth roughly what it owes.
Total debt $5.3M against a stock market value of $259.3M.
Distance to default 2.72 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.3M (short-term plus half of long-term), stock volatility 141.2%; Altman Z'' 12.11. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.04 (down 99.5%), Q32 Bio Inc. would be worth roughly what it owes.
Total debt $5.3M against a stock market value of $259.3M.
Distance to default 2.72 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.3M (short-term plus half of long-term), stock volatility 141.2%; Altman Z'' 12.11. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
8 relationships7
As Filer
counterparties named
1
As Counterparty
mentioned by others
2
Rel. Types
2022-02-03
Earliest Filing
2026-03-27
Latest Filing
partner: 6
acquirer: 1
Counterparties (Filed by QTTB)
7 relationshipsCompanies named in QTTB's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Cantor Fitzgerald & Co. | — | partner | Sales Agent for the Company's at-the-market offering program. | 2026-03-27 | View |
| Akebia Therapeutics, Inc. | AKBA | acquirer | Acquired substantially all assets related to ADX-097 from Q32 Bio Inc. | 2025-12-01 | View |
| Oxford Biomedica Solutions LLC | — | partner | Joint venture entity formed to operate AAV vector manufacturing | 2022-03-16 | View |
| Oxford Biomedica (US), Inc. | — | partner | Majority equity holder and cash contributor to Newco | 2022-03-16 | View |
| Oxford Biomedica plc | — | partner | Parent company of Oxford Biomedica (US), Inc. | 2022-03-16 | View |
| Oxford Biomedica (US), Inc. | — | partner | Joint venture partner and investor in Newco | 2022-02-03 | View |
| Oxford Biomedica plc | — | partner | Parent company of Oxford Biomedica (US), Inc. and joint venture partner in Newco | 2022-02-03 | View |
Mentioned As Counterparty
1 mentionsOther companies that named QTTB in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-30 | Regulation FD; Other Events; Exhibits | View | |
| 2026-09-14 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-07-15 | Material Agreement; Exhibits | Agreement | View |
| 2026-07-13 | Regulation FD; Other Events; Exhibits | View | |
| 2026-07-13 | Other Events; Exhibits | View | |
| 2026-06-16 | Shareholder Vote | View | |
| 2026-05-27 | Material Agreement; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-04-24 | Other Events; Exhibits | View | |
| 2026-03-27 | Material Agreement; Exhibits | Agreement | View |
| 2026-03-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-17 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-12-19 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-12-01 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Completion o | Agreement Acquisition | View |
| 2025-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-21 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-25 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-06-17 | Material Modification to Rights of Security Holders; Amendments to Articles of Incorporation or Byla | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR